Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 10/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 8/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769417 | 0.94 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL3768887 | 0.94 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL3773653 | 0.88 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL3769681 | 0.87 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL3776037 | 0.86 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL3770526 | 0.86 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL3770947 | 0.85 | SLC5A2 (0.68) | SLC5A2SLC5A1 | |
| SCHEMBL3779163 | 0.84 | SLC5A2 (0.60) | SLC5A2SLC5A1 | |
| SCHEMBL3768991 | 0.83 | SLC5A1 (0.43) | SLC5A2SLC5A1 | |
| SCHEMBL3773754 | 0.82 | SLC5A1 (0.53) | SLC5A2SLC5A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | claimed |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | IAPP, G6PC1, GPR119 | SLC5A2 6/4885SLC5A1 4/4885CYP3A4 913/4885 |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | SLC5A1, SLC5A2, G6PC1 | SLC5A2 2/4885SLC5A1 1/4885CYP3A4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.